Prostatic Hyperplasia and Social Class

Prostatic Hyperplasia and Social Class.

Prostatic cancer and social class.

Over the last 30 years the death rate from prostatic cancer in Scotland has remained at about 17 per 100,000 in the age group 55-64 years, but at age 65-74 years the rate has increased from 64 in1930-32 to 106 per 100,000 in 1963, and in men aged 85 and over the rate has gone up from 86 to 476 per 100,000 in the same period (Registrar General for Scotland, 1963). This steep rise in mortality in...

Therapeutic Class Overview Benign Prostatic Hyperplasia (BPH) Treatments

Therapeutic Class  Overview/Summary: The agents approved for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) will be the focus of this review. The α-adrenergic blockers including, alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, reduce smooth-muscle tone in the prostate and bladder neck decreasing lower urinary tract symptoms (LUTS) secondary to BPH. Alfuzo...

Comparison of Matrix Metalloproteinases 2 mRNA Expression in Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia

Background and Aims: Prostate cancer is the second most common cancer in men worldwide in men. Matrix metalloproteinase 2 (MMP2) has a role in the invasion and destruction of the basement membrane and the extra-cellular matrix and facilitating the process of tumor cell invasion. The present study was conducted to compare the expression of MMP2 gene in prostate cancer (PCa) and benign prostatic ...

Nutrition and benign prostatic hyperplasia.

PURPOSE OF REVIEW Nutrition seems to modify the pathogenesis of benign prostatic hyperplasia (BPH) effect symptomology in men suffering from lower urinary tract symptoms (LUTS). Although there are numerous pharmaceuticals and procedures for these conditions, nutrition may improve outcomes as a primary approach or in tandem with BPH medications or procedures. The purpose of this review is to hig...